PharmaEssentia Corporation (TPE:6446)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
1,380.00
+15.00 (1.10%)
Nov 13, 2026, 1:30 PM CST

PharmaEssentia Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
9,0795,0452,966-623.84-1,375-2,811
Depreciation & Amortization
441.49351.55336.99250.58225.38226
Other Amortization
47.0547.0530.7218.182.541.09
Loss (Gain) From Sale of Assets
1.582.030.93-0.10.07
Loss (Gain) on Equity Investments
9.124.46----
Stock-Based Compensation
1,744463.47164.39710.21216.21501.52
Other Operating Activities
1,135-302.77-275.6-383.62-464.9311.18
Change in Accounts Receivable
-2,406-1,849-1,312-513.66-332.6-15.45
Change in Inventory
-572.5-62.2125.34-356.61-240.66-466.53
Change in Accounts Payable
-76.3330.27-2.44-102.0554.62-0.69
Change in Unearned Revenue
12.23-0.230.23---
Change in Other Net Operating Assets
897.41,547590.17291.29408.6891.74
Operating Cash Flow
10,3155,2782,525-709.51-1,505-2,462
Operating Cash Flow Growth
139.04%109.04%----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-3,450-1,911-862-1,286-312.03-70.33
Cash Acquisitions
-948.36-----
Sale (Purchase) of Intangibles
-14.41-12.51-41.49-41.65-8.72-27.54
Investment in Securities
-846.49-440.1-423.65-96--25
Other Investing Activities
-149.85-111.32-7.76937.04-922.0744.7
Investing Cash Flow
-5,409-2,475-1,335-486.65-1,243-78.18

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-2,243-1973.88-
Total Debt Issued
2,2432,243-1973.88-
Short-Term Debt Repaid
--2,243-21-973.88--30
Long-Term Debt Repaid
--229.31-233.12-150.97-127.41-116.23
Lease Payments
-178.78-217.41-220.77-138.93-115.38-109.67
Total Debt Repaid
-2,428-2,472-254.12-1,125-127.41-146.23
Net Debt Issued (Repaid)
-185.84-229.31-254.12-1,124846.47-146.23
Issuance of Common Stock
109.9995.5591.114,3308,7433,045
Repurchase of Common Stock
----2,718--87.5
Common Dividends Paid
-556.73-366.17----
Other Financing Activities
140.27---34.56-10.26-2.41
Financing Cash Flow
-492.32-499.93-163.0210,4549,5792,809

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
769.51-660.75358.27104.1119-15.25
Net Cash Flow
5,1831,6421,3859,3626,850253.27

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
6,8653,3661,663-1,996-1,818-2,532
Free Cash Flow Growth
126.92%102.47%----
Free Cash Flow Margin
27.89%21.53%17.08%-39.09%-63.06%-385.74%
Free Cash Flow Per Share
16.628.184.04-5.03-5.20-7.91
Levered Free Cash Flow
4,3212,12621.42-1,292-2,589-1,316
Unlevered Free Cash Flow
4,3362,14235.29-1,263-2,577-1,310
Free Cash Flow After Leases
6,6863,1491,442-2,134-1,933-2,642

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
24.6525.5322.1934.5610.262.41
Cash Income Tax Paid
589.64232.89297.976.875.68-0
Change in Working Capital
-2,145-333.28-698.22-681.02-109.97-390.93